Fenretinide

Generic Name
Fenretinide
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C26H33NO2
CAS Number
65646-68-6
Unique Ingredient Identifier
187EJ7QEXL
Background

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Indication

Investigated for use/treatment in macular degeneration.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers

Phase 1
Completed
Conditions
Safety and Tolerability
Interventions
Drug: Placebo
Drug: Fenretinide
First Posted Date
2023-12-26
Last Posted Date
2024-02-23
Lead Sponsor
Island Pharmaceuticals
Target Recruit Count
25
Registration Number
NCT06181760
Locations
🇦🇺

Island Site 01, Randwick, New South Wales, Australia

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

First Posted Date
2020-01-21
Last Posted Date
2024-12-16
Lead Sponsor
SciTech Development, LLC
Target Recruit Count
46
Registration Number
NCT04234048
Locations
🇺🇸

City of Hope Medical Foundation, Duarte, California, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

and more 5 locations

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

Phase 2
Conditions
Peripheral T-cell Lymphoma
Interventions
Drug: Fenretinide
First Posted Date
2015-07-13
Last Posted Date
2019-07-23
Lead Sponsor
CerRx, Inc.
Target Recruit Count
140
Registration Number
NCT02495415
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Baylor University Medical Center, Dallas, Texas, United States

🇺🇸

Norton Healthcare, Louisville, Kentucky, United States

and more 8 locations

Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis

Phase 1
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: Placebo
Drug: Fenretinide
First Posted Date
2014-05-20
Last Posted Date
2016-07-12
Lead Sponsor
Elias Matouk
Target Recruit Count
15
Registration Number
NCT02141958
Locations
🇨🇦

Montreal Chest Institute, Montreal, Quebec, Canada

Fenretinide in Healthy Young Women at Genetic and Familial Risk

Phase 3
Terminated
Conditions
High-Risk Cancer
Interventions
Other: Placebo
Drug: Fenretinide
First Posted Date
2011-11-24
Last Posted Date
2018-11-07
Lead Sponsor
European Institute of Oncology
Target Recruit Count
20
Registration Number
NCT01479192
Locations
🇮🇹

European Institute of Oncology, Milan, Italy

Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

First Posted Date
2010-08-24
Last Posted Date
2022-03-31
Lead Sponsor
South Plains Oncology Consortium
Target Recruit Count
3
Registration Number
NCT01187810
Locations
🇺🇸

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

First Posted Date
2008-03-28
Last Posted Date
2023-04-07
Lead Sponsor
Nant Operations Center
Target Recruit Count
17
Registration Number
NCT00646230
Locations
🇺🇸

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States

🇨🇦

Hospital for Sick Children, Toronto, Ontario, Canada

🇺🇸

Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States

and more 10 locations

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

Phase 2
Suspended
Conditions
Obesity
Insulin Resistance
Interventions
Drug: Placebo
Drug: Fenretinide
First Posted Date
2007-10-19
Last Posted Date
2021-02-10
Lead Sponsor
University of California, San Diego
Target Recruit Count
21
Registration Number
NCT00546455
Locations
🇺🇸

University of California at San Diego Hospitals, San Diego, California, United States

Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients

First Posted Date
2007-09-26
Last Posted Date
2010-06-29
Lead Sponsor
Beersheva Mental Health Center
Registration Number
NCT00534898
Locations
🇮🇱

Be'er Sheva Mental Health Center, Sha'ar Menashe Mental Health Center, Be'er Sheva, Hadera, Israel

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

First Posted Date
2007-02-01
Last Posted Date
2010-06-22
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
245
Registration Number
NCT00429936
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy